Scytovirin Domain 1 Related Polypeptides

Despite therapeutic advances, human immunodeficiency virus (HIV) is still a pervasive disease, with approximately 37 million people infected worldwide. Peptides have become popular therapeutic agents, as these proteins offer structural diversity for many different diseases. Several peptides were commercially developed as HIV therapeutics, demonstrating the high potential for peptides in treating HIV.  Researchers at the National Cancer Institute developed a novel small polypeptide, known as SD1, for use as an HIV therapeutic. SD1 is derived from scytovirin, a potent anti-HIV protein isolated from the cyanobacterium Scytonema varium. SD1 has demonstrated low nanomolar activity against laboratory HIV strains and inhibits HIV by blocking viral fusion. SD1 is a lectin with specificity for viral envelope glycoproteins.  IC: NCINIH Ref. No.: E-180-2005Advantages: Small size allows for decreased immunogenicitySmall size allows for easy synthesis using automated techniquesLow nanomolar activity against HIV strainsPossible activity against additional viruses due to its ability to target viral envelope glycoproteins through a lectin mechanismApplications: Anti-HIV microbicideAnti-HIV therapeuticDevelopment Status: Basic (Target Identification)Updated On: Jul 27, 2018Provider Classifications: Date Published: Friday, July 27, 2018Publications: Patent Number: 8,067,5308,481,2551,891,094Licensing Contacts: Lead Inventor: Invento...

Source: NIH OTT Licensing Opportunities - July 27, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research